Lancet Oncol 2010, 11:412–413. 11. Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim HY, Sung JH, Lee JS: First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. J Thorac Oncol 2010, 5:361–368.PubMedCrossRef 12. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K, North East Japan Gefitinib Study Group: selleck chemicals First-line gefitinib for patients with advanced non-small-cell

lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol

2009, 27:1350–1354.CrossRef 13. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in BIX 1294 clinical trial pulmonary adenocarcinoma. N Engl J Med 2009, 361:947–957.PubMedCrossRef 14. Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ: Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 2009, 76:239–246.PubMedCrossRef 15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG, Smad inhibitor European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute

of Canada: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205–216.PubMedCrossRef 16. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM: Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer 1993,29A(Suppl 1):S51–58.PubMedCrossRef Oxaprozin 17. Shun Lu, Ziming Li: Targeted therapy of lung cancer-data from Asia. China oncology 2007, 17:8–13. 18. Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC: Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 2006, 107:1873–1882.PubMedCrossRef 19. Moiseenko VM, Protsenko SA, Semenov II, Moiseenko FV, Levchenko EV, Barchuk AS, Matsko DE, Ivantsov AO, Ievleva AG, Mitiushkina NV, Togo AV, Imianitov EN: Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study). Vopr Onkol 2010, 56:20–23.PubMed 20.